Skip to content
Screener

Stoke Therapeutics, Inc. STOK Net debt / EBITDA

Net debt / EBITDA at other companies

Jazz Pharmaceuticals logo
Jazz PharmaceuticalsJAZZ
5.6×-2.2×
Harmony Biosciences Holdings, Inc. logo
Harmony Biosciences Holdings, Inc.HRMY
-2×+1.3×

Other financials

Income statement

See full
Revenue$6.2M-96.1%
Operating income-$53.4M-148%
Net income-$50.0M-144%
EPS (diluted)-$0.79-142%

Balance sheet

See full
Cash & equivalents$155.7M-43.4%
Total debt$3.4M-42.5%
Total equity$394.9M+12.8%
Total assets$443.3M+8.9%

Cash flow

See full
Operating cash flow-$60.6M-146%
CapEx$353.0K+132%
Free cash flow-$60.9M-146%

Valuation

See full
Market cap$2.06B+187%
Enterprise value$1.91B+206%
P/S64.2×+60.6×

Profitability

See full
Operating margin-577.5%-597pp
Net margin-529.2%-556pp
FCF margin36.2%+18.4pp

Returns & leverage

See full
Return on equity-45.6%-66.1pp
Debt / equity0×0.0×
Current ratio9×+0.6×

Where this comes from

Calculated from Stoke Therapeutics, Inc.’s reported figures.

net debt/ebitda=-2.8×

Based on the most recent quarter.

The source filing: Stoke Therapeutics, Inc.’s 10-Q, filed November 4, 2025. Open the filing →

Filed
Nov 4, 2025
Fiscal quarter
Q3 FY2025
Calendar quarter
Q3 2025
Accession
0001193125-25-264720

FAQ

What is Stoke Therapeutics, Inc.'s net debt / EBITDA?
Stoke Therapeutics, Inc. (STOK) reported net debt / EBITDA of -2.8× in Q3 2025.
What does net debt / EBITDA mean?
Net debt (total debt minus cash) divided by trailing-twelve-month EBITDA. Expresses leverage in years — roughly how long it would take to repay net debt out of operating cash earnings.

Ask your AI about Stoke Therapeutics, Inc.'s net debt / ebitda.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude